Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR) - Doehner, H; Vyas, P; Seymour, JF; Santini, V; Stone, RM; Minden, MD; Al-Ali, HK; Del Castillo, TB; Morrill, J; Songer, S; Weaver, J; Skikne, BS; et al. (American Society of Hematology, 2016)